|
|
Taiwan Academic Institutional Repository >
Browse by Title
|
Showing items 887406-887415 of 2348719 (234872 Page(s) Totally)
<< < 88736 88737 88738 88739 88740 88741 88742 88743 88744 88745 > >>
View [10|25|50] records per page
| 國立臺灣大學 |
2005 |
Trastuzumab after Adjuvant Chemotherapy in Her2-Positive Breast Cancer
|
黃俊升; HUANG, CHUN-FANG; LEE, FANG-JEN S |
| 國立臺灣大學 |
2005-06 |
TRASTUZUMAB AFTER ADJUVANT CHEMOTHERAPY IN HER2-POSITIVE BREAST CANCER
|
黃俊升 |
| 臺大學術典藏 |
2020-03-23T07:19:34Z |
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
|
Gelber R.D.; Dolci M.S.; McFadden E.; Straehle C.; Ward C.; Greatorex V.; S?to T.; R?schoff J.; Suter T.M.; Lohrisch C.; Iwata H.; Thomssen C.; Nitz U.; L?ng I.; Lichinitser M.; Inbar M.; Piccart-Gebhart M.J.;Procter M.;Leyland-Jones B.;Goldhirsch A.;Untch M.;Smith I.;Gianni L.;Baselga J.;Bell R.;Jackisch C.;Cameron D.;Dowsett M.;Barrios C.H.;Steger G.;Chiun-Sheng Huang;Andersson M.;Inbar M.;Lichinitser M.;L?Ng I.;Nitz U.;Iwata H.;Thomssen C.;Lohrisch C.;Suter T.M.;R?Schoff J.;S?To T.;Greatorex V.;Ward C.;Straehle C.;Mcfadden E.;Dolci M.S.;Gelber R.D.; Piccart-Gebhart M.J.; Procter M.; Leyland-Jones B.; Goldhirsch A.; Untch M.; Smith I.; Gianni L.; Baselga J.; Bell R.; Jackisch C.; Cameron D.; Dowsett M.; Barrios C.H.; Steger G.; CHIUN-SHENG HUANG; Andersson M. |
| 國家衛生研究院 |
2024-09 |
Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)
|
Janjigian, YY;van Laarhoven, HWM;Rha, SY;Kozlov, V;Oh, DY;Gravina, A;Rapatoni, L;Shoji, H;Hofheinz, RD;Chen, LT;Ford, HER;Chenard-Poirier, M;Raoufmoghaddam, S;Lloyd, C;Zhang, C;Mateo, C;Lee, J |
| 國立成功大學 |
2022 |
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
|
Cort�s, J.;Kim, S.-B.;Chung, W.-P.;Im, S.-A.;Park, Y.H.;Hegg, R.;Kim, M.H.;Tseng, L.-M.;Petry, V.;Chung, Chung C.-F.;Iwata, H.;Hamilton, E.;Curigliano, G.;Xu, B.;Huang, C.-S.;Kim, J.H.;Chiu, J.W.Y.;Pedrini, J.L.;Lee, C.;Liu, Y.;Cathcart, J.;Bako, E.;Verma, S.;Hurvitz, S.A.;Investigators, DESTINY-Breast03 Trial |
| 國立成功大學 |
2024-09 |
Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
|
Iwata;Hiroji;Xu;Binghe;Kim;Sung-Bae;Chung;Wei-Pang;Park;Hee, Yeon;Kim;Hwan, Min;Tseng;Ling-Ming;Chung;Chi-Feng;Huang;Chiun-Sheng;Kim;Hyun, Jee;Chiu;Yan, Joanne Wing;Yamashita;Toshinari;Li;Wei;Egorov;Anton;Nishijima;Soichiro;Nakatani;Shunsuke;Nishiyama;Yuji;Sugihara;Masahiro;Cortes;Javier;Im;Seock-Ah |
| 國立成功大學 |
2024-05 |
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial
|
Hurvitz;S, A.;Kim;S, -B.;Chung;W, -P.;Im;S, -A.;Park;Y, H.;Hegg;R;Kim;M, -H.;Tseng;L, -M.;Petry;V;Chung;C, -F.;Iwata;H;Hamilton;E;Curigliano;G;Xu;B;Egorov;A;Liu;Y;Cathcart;J;Bako;E;Tecson;K;Verma;S;Cortes;J |
| 國立成功大學 |
2023 |
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|
Hurvitz, S.A.;Hegg, R.;Chung, W.-P.;Im, S.-A.;Jacot, W.;Ganju, V.;Chiu, J.W.Y.;Xu, B.;Hamilton, E.;Madhusudan, S.;Iwata, H.;Altintas, S.;Henning, J.-W.;Curigliano, G.;Perez-Garcia, J.M.;Kim, S.-B.;Petry, V.;Huang, C.-S.;Li, W.;Frenel, J.-S.;Antolin, S.;Yeo, W.;Bianchini, G.;Loi, S.;Tsurutani, J.;Egorov, A.;Liu, Y.;Cathcart, J.;Ashfaque, S.;Cort�s, J. |
| 臺大學術典藏 |
2021-06-04T05:10:19Z |
Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study
|
CHIUN-SHENG HUANG; Yang, Youngsen; Kwong, Ava; Chen, Shin-Cheh; Tseng, Ling-Ming; Liu, Mei-Ching; Shen, Kunwei; Wang, Shusen; Ng, Ting-Ying; Feng, Yi; Sun, Guofang; Yan, Iris Renfei; Shao, Zhimin |
| 臺大學術典藏 |
2019 |
Trastuzumab emtansine for residual invasive HER2-positive breast cancer
|
Von Minckwitz G.; CHIUN-SHENG HUANG; Geyer C.E.; Jr.; Singel S.M.; Douthwaite H.; Smitt M.; Tesarowski D.; Lam L.H.; Wu H.; Caremoli E.R.; Shao Z.; W?lfing P.; Crown J.P.; Fasching P.A.; DiGiovanna M.P.; Jackisch C.; Wapnir I.L.; Arce-Salinas C.; Jacot W.; Conlin A.K.; Fischer H.H.; Mano M.S.; Loibl S.; Mamounas E.P.; Untch M.; Wolmark N.; Rastogi P.; Schneeweiss A.; Redondo A.; Von Minckwitz G.;Chiun-Sheng Huang;Mano M.S.;Loibl S.;Mamounas E.P.;Untch M.;Wolmark N.;Rastogi P.;Schneeweiss A.;Redondo A.;Fischer H.H.;Jacot W.;Conlin A.K.;Arce-Salinas C.;Wapnir I.L.;Jackisch C.;Digiovanna M.P.;Fasching P.A.;Crown J.P.;W?Lfing P.;Shao Z.;Caremoli E.R.;Wu H.;Lam L.H.;Tesarowski D.;Smitt M.;Douthwaite H.;Singel S.M.;Geyer C.E.;Jr. |
Showing items 887406-887415 of 2348719 (234872 Page(s) Totally)
<< < 88736 88737 88738 88739 88740 88741 88742 88743 88744 88745 > >>
View [10|25|50] records per page
|
